PHAT

SEC source: 0001193125-25-220950 · ownership.xml · nonDerivative · entry 1

Basta Steven L · CIK 0001417397 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-113822 · ownership.xml · nonDerivative · entry 1

Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,931

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

SEC source: 0000950170-25-096917 · ownership.xml · nonDerivative · entry 1

Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,392

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in mutliple transactions at prices $8.364 and $8.35. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-089513 · ownership.xml · derivative · entry 1

Cook Anne Marie · CIK 0001320559 · Chief Legal Off. & Corp. Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2035-06-22

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on June 23, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0000950170-25-082453 · ownership.xml · derivative · entry 2

FIELDS HEIDI · CIK 0001014330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0000950170-25-082453 · ownership.xml · nonDerivative · entry 1

FIELDS HEIDI · CIK 0001014330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-082448 · ownership.xml · derivative · entry 2

Stenhouse Mark · CIK 0001734751 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0000950170-25-082448 · ownership.xml · nonDerivative · entry 1

Stenhouse Mark · CIK 0001734751 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-082456 · ownership.xml · derivative · entry 2

COLA MICHAEL F · CIK 0001188940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0000950170-25-082456 · ownership.xml · nonDerivative · entry 1

COLA MICHAEL F · CIK 0001188940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,798

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-082458 · ownership.xml · derivative · entry 2

KARBE FRANK · CIK 0001276700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0000950170-25-082458 · ownership.xml · nonDerivative · entry 1

KARBE FRANK · CIK 0001276700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,500

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-082454 · ownership.xml · derivative · entry 6

Topper James N · CIK 0001341382 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-06-02

F6 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the firstanniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vestingdate.

SEC source: 0000950170-25-082454 · ownership.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,596

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-082445 · ownership.xml · derivative · entry 2

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0000950170-25-082445 · ownership.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,500

F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001415889-25-014428 · form4-05232025_080527.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 59,403

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.76 to $3.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000950170-25-075870 · ownership.xml · derivative · entry 1

Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2035-05-18

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on May 19, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0001415889-25-013134 · form4-05152025_080534.xml · nonDerivative · entry 2

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 55,623

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.215 to $3.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-013134 · form4-05152025_080534.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 49,323

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.045 to $3.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-012770 · form4-05132025_080500.xml · nonDerivative · entry 3

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 48,203

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.825 to $3.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4

F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-012770 · form4-05132025_080500.xml · nonDerivative · entry 2

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 35,602

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-25-012770 · form4-05132025_080500.xml · nonDerivative · entry 1

Topper James N · CIK 0001341382 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 33,376

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $3.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000950170-25-067237 · ownership.xml · nonDerivative · entry 2

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,500

SEC source: 0000950170-25-067237 · ownership.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,500

SEC source: 0000950170-25-054886 · ownership.xml · derivative · entry 2

Schroeder Theodore R · CIK 0001378690 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-04-15

F2 · derivative.exercise_date: The stock option will vest with respect to one-third (1/3) of the shares of common stock on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0000950170-25-054886 · ownership.xml · nonDerivative · entry 1

Schroeder Theodore R · CIK 0001378690 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

F1 · shares: Represents restricted stock units ("RSUs") granted on April 16, 2025. One-third (1/3) of the total number of RSUs granted vest on April 16, 2026, and will vest in substantially equal quarterly installments over the twenty-four (24) months thereafter, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-052156 · ownership.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,868

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $4.55 to $4.57. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-050621 · ownership.xml · derivative · entry 2

Basta Steven L · CIK 0001417397 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,085,000

Underlying: Common Stock · 1,085,000 shares

Expires 2035-04-02

F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on April 3, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0000950170-25-050621 · ownership.xml · derivative · entry 1

Basta Steven L · CIK 0001417397 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2 · derivative.exercise_date: The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date.

F2 · derivative.expiration_date: The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date.

SEC source: 0000950170-25-040325 · ownership.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.29 to $4.55. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-031048 · ownership.xml · derivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,500

Underlying: Common Stock · 342,500 shares

Expires 2035-02-26

F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0000950170-25-031042 · ownership.xml · derivative · entry 3

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-02-26

F2 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0000950170-25-031042 · ownership.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,546

F1 · shares: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-031034 · ownership.xml · derivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-02-26

F2 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0000950170-25-031034 · ownership.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312,590

F1 · shares: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-25-008348 · ownership.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,465

F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6503. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,840 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.

SEC source: 0000950170-25-008357 · ownership.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,546

F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $6.5855 to $6.6519. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.

SEC source: 0000950170-25-008353 · ownership.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,390

F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6650. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.

SEC source: 0000950170-24-139062 · ownership.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,156

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

SEC source: 0000950170-24-139063 · ownership.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,303

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

SEC source: 0000950170-24-136391 · ownership.xml · nonDerivative · entry 1

KARBE FRANK · CIK 0001276700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $8.00. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-136390 · ownership.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.9999 to $8.2496. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-043291 · ownership.xml · derivative · entry 2

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2033-05-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-043291 · ownership.xml · nonDerivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The amount in column 5 shows the amount beneficially owned as of the filing date of this report.

SEC source: 0000950170-24-084179 · ownership.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 377,734

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · balance_after: Includes 798 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024.

SEC source: 0000950170-24-084182 · ownership.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,447

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · balance_after: Includes 1,009 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024.

SEC source: 0000950170-24-084186 · ownership.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,421

F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

F2 · balance_after: Includes 1,754 shares acquired in January 2024 and 1 share acquired in July 2024 under the Phathom Pharmaceuticals, Inc. employee stock purchase plan

SEC source: 0000950170-24-067548 · ownership.xml · nonDerivative · entry 1

Henderson Molly · CIK 0001363812 · CFO and CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,763

F1 · shares: Represents restricted stock units ("RSUs") granted on May 31, 2024. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of December 18, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0000950170-24-067539 · ownership.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,567

F1 · shares: Represents restricted stock units ("RSUs") granted on May 31, 2024. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of December 18, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.